Outcome of chemotherapy extravasation in a large patient series using a standardised management protocol

Support Care Cancer. 2015 Jun;23(6):1741-8. doi: 10.1007/s00520-014-2535-2. Epub 2014 Nov 30.

Abstract

Purpose: In a longitudinal observation, extravasation of antitumoural compounds and the efficacy of its structured interdisciplinary management were assessed in a routine setting.

Methods: One hundred sixty-nine patients with extravasation of cytotoxics were managed according to a prospective approach documenting the extravasated compound, localisation, duration until full symptom resolution and sequelae. Surgery was implemented in the case of failure of conservative measures.

Results: In 155 (91.7 %) out of 169 patients, conservative management was successful (surgical intervention, 14 patients). Extravasations of anthracyclines (N = 44), platinum compounds (N = 41), vinca alkaloids (N = 20) and taxanes (N = 19) were often associated with erythema, oedema and pain. The median period until full resolution of symptoms differed among the administered cytotoxics (anthracyclines, 55 days; taxanes and vinca alkaloids, 27 days; platinum compounds, 14 days) with statistical significance between the vesicants. Histologically, surgically resected specimens showed extensive necrotic areas with inflammatory infiltrates at the periphery of the removed lesions.

Conclusions: In a routine setting, the standardised management of cytotoxic extravasations by an interdisciplinary task force resulted in a satisfactory outcome. When surgical intervention was indicated, complete remission of the lesions within a median of 14 days reduced the delay in the administration of further chemotherapy to a minimum. The proposed approach is therefore considered as suitable to manage extravasations in cancer chemotherapy in a large number of subjects and to ensure patient adherence to cytotoxic treatment.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anthracyclines / adverse effects
  • Anthracyclines / therapeutic use
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use*
  • Cisplatin / adverse effects
  • Cisplatin / therapeutic use
  • Dioxoles / therapeutic use
  • Extravasation of Diagnostic and Therapeutic Materials / epidemiology*
  • Extravasation of Diagnostic and Therapeutic Materials / therapy*
  • Female
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Prospective Studies
  • Remission Induction
  • Taxoids / adverse effects
  • Taxoids / therapeutic use
  • Tetrahydroisoquinolines / therapeutic use
  • Trabectedin
  • Treatment Outcome
  • Vinca Alkaloids / adverse effects
  • Vinca Alkaloids / therapeutic use
  • Young Adult

Substances

  • Anthracyclines
  • Antineoplastic Agents
  • Dioxoles
  • Taxoids
  • Tetrahydroisoquinolines
  • Vinca Alkaloids
  • Trabectedin
  • Cisplatin